Phaseline

Companies › Chengdu Anticancer Bioscience

Chengdu Anticancer Bioscience: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Jun 2029.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
JMBI-001
MYC inhibitor
–Phase 1Advance Solid TumorsJun 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07864701JMBI-001Phase 1Advance Solid TumorsOncologyJun 2029

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.